EGFR and non-small cell lung carcinoma: Consequently, this economic evaluation did not incorporate other treatment strategies, such as bevacizumab plus chemotherapy, despite its status as the standard-of-care for patients with EGFR-mutated NSCLC who have progressed on EGFR TKI treatment.